<DOC>
	<DOCNO>NCT00963820</DOCNO>
	<brief_summary>The primary objective study determine safety profile , tolerability , maximum tolerate dose ixazomib citrate ( MLN9708 ) take orally weekly dosing schedule patient relapse refractory multiple myeloma ( RRMM ) . Secondary objective include pharmacokinetics response rate .</brief_summary>
	<brief_title>Study Evaluating Safety Tolerability Weekly Dosing Oral IXAZOMIB Adult Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>The drug test study call ixazomib citrate ( MLN9708 ) . Ixazomib citrate test people multiple myeloma relapse treatment become unresponsive treatment . This study determine maximum tolerate dose ( MTD ) ixazomib citrate use dose escalation scheme . Once MTD establish , participant enrol MTD one 4 expansion cohort characterize safety , tolerability efficacy MLN9708 . Blood sample safety lab , hematology , serum chemistry pharmacokinetic evaluation obtain timepoints specify . Disease response assessment perform first day every cycle begin Cycle 3 . The study enroll approximately 60 patient . All participant receive treatment ixazomib citrate . This multi-center trial conduct United States . The overall time participate study 60 day , participant make 12-16 visit clinic study procedure .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Each patient must meet following eligibility criterion enrol study : Adult patient multiple myeloma relapse follow least 2 line therapy . Patients must measurable disease . Appropriate functional status , include recovery effect prior antineoplastic therapy , acceptable organ function describe protocol . Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception abstain heterosexual intercourse . Male patient agree practice effective barrier contraception agree abstain heterosexual intercourse . Willing able give write informed consent . Suitable venous access studyrequired blood sampling . Peripheral neuropathy great equal Grade 2 . Major surgery , serious infection , infection require systemic antibiotic therapy within 14 day first dose study drug . Lifethreatening illness unrelated cancer . Diarrhea great Grade 1 outline protocol Systemic antineoplastic radiation therapy within 14 day cytotoxic agent , treatment investigational product within 21 day first dose study treatment . Treatment investigational proteasome inhibitor . Systemic treatment prohibit medication outline protocol within 14 day study treatment . Ongoing therapy corticosteroid great 10mg prednisone equivalent per day . Central nervous system involvement . Evidence current uncontrolled cardiovascular condition , include cardiac arrhythmia , congestive heart failure , angina , myocardial infarction within past 6 month . Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigenpositive status , know suspect active hepatitis C infection . Serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Known gastrointestinal ( GI ) disease GI procedure could interfere oral absorption tolerance IXAZOMIB include difficulty swallowing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Relapsed multiple myeloma</keyword>
	<keyword>Refractory multiple myeloma</keyword>
	<keyword>Drug therapy</keyword>
</DOC>